$AVR

L1 Capital Pty Ltd sold $5.8M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 627,659 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $9.22 ($9.10–$9.30, $5.79M total) across 2 trades over 2026-08-10 to 2026-08-11.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 12, 2026, 10:13 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A reported open-market sale of about $5.79M worth of shares can influence short-term sentiment and trading flows, but it does not constitute new operational or financial guidance.

02

Market read

Traders may monitor AVR for sentiment effects around insider-related selling, but the filing alone is unlikely to drive a durable repricing without accompanying fundamentals.

03

What to watch

The trades are indirect holdings and the filing does not provide the reason for sale; absence of a stated 10b5-1 plan can be misread without additional context.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-12, covering sales dated 2026-08-10 to 2026-08-11

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp (AVR) by L1 Capital Pty Ltd, identified as a 10% owner with indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 627,659 Anteris Technologies Global Corp shares in open-market trades at about $9.10 to $9.30.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows transaction size and pricing, but it is not a guidance, contract, or regulatory catalyst; also no 10b5-1 plan is indicated, which can increase attention but not guarantee directionality.

Market effects

No direct sector read-through; this is a single-issuer ownership transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven or part of a broader portfolio rebalancing, so it may not signal negative company outlook.

Key entities

  • Anteris Technologies Global Corp

    Subject of the Form 4 disclosure, ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale of AVR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.